On December 31, 2021 Helix BioPharma Corp. (TSX: HBP) ("Helix" or the "Company"), an immuno-oncology
company developing innovative drug candidates for the prevention and treatment of cancer, reported a
corporate update on initiatives that were undertaken by the Company in 2021 (Press release, Helix BioPharma, DEC 31, 2021, View Source [SID1234608311]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Despite the challenges brought about by the COVID-19 pandemic, 2021 was a productive year for the Company.
During the second half of 2021, the Company initiated efforts to validate Helix and its lead clinical program with
external stakeholders to bring in an outside perspective to the company’s strategy and future, including but not limited to the following actions:
• In May of 2021, Helix engaged the consulting services of Dr. Christof Boehler, PhD, a seasoned biotechnology
scientist and entrepreneur to assess Helix and its assets. The outcome of this engagement was a positive outlook
on the potentials of L-DOS47, which has been demonstrated as safe in approximately 100 patients to date in the
Company’s Phase 1 clinical trials. Given the limitations of the current standard of care in addressing the high
unmet medical needs in oncology, the Company believes that the unique characteristics of L-DOS47 position
Helix as one of the leaders in the development of newer avenues like tumor microenvironments (change of tumor
pH), with an aim of improving the outcome of treatment of various malignancies with the use of L-DOS47 in
combination with immunotherapy and/or chemotherapy.
• In addition to Dr. Boehler’s assessment, Helix also retained the services of a highly experienced oncology
consultancy, Cello Healthcare ("Cello"), in August of 2021. A major aspect of this engagement included
interviews with certain key opinion leaders in the field to obtain their feedback and recommendations on the
Company’s L-DOS47 technology platform. The outcome of these interviews conducted by Cello both validated
the clinical work completed by Helix to date, and also helped the Company identify additional opportunities to
further strengthen and de-risk the Company’s clinical program, including optimal selection of patients for trials
(stratification) based on objective biomarkers, among other criteria. The Company anticipates that these activities
will facilitate strategic dialogue with potential market leaders in cancer treatment, and that the additional preclinical data obtained will further enhance the Company’s clinical program design.
• Finally, in September of 2021, Helix retained the consultancy services of Dr. Atul Deshpande, PhD, MBA, another
seasoned biotech executive who helped his previous employer, an immuno-oncology company, raise significant
funds from venture capital funds, and designed a focused strategy and execution plan in furtherance of the
Company’s public listing and significant concurrent financing. In his consulting role, Dr. Deshpande has been
tasked with implementing a refreshed corporate strategy and clinical plans to help the Company reach its goals.

Dr. Slawomir Majewski, Interim CEO and Director, states "We are hopeful that this kind of external validation
combined with internal expertise and experience will enable Helix to remain focused on the progression towards
developing unique therapies in the field of immuno-oncology for the treatment of cancer. We will continue to partner with these experienced advisors and experts in the field with an aim of enhancing the value of our platform and assets."

"Our clinical program remains our highest priority to ensure we deliver on a substantial data package that would
ultimately benefit patients and stakeholders alike. We await the final trial reports of the Phase I and II studies in lung
cancer in 2022. The other clinical trial in pancreatic cancer continues and we remain committed to this study. In
addition, in May 2021, we announced an agreement with Lind Global Macro Fund, LP, and subsequently closed a
first tranche financing for gross proceeds of $3,500,000. We are also working diligently to identify potential candidates to act as the Company’s permanent CEO," continued Dr. Majewski.

On December 31, 2021 I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, reported its participation in the following conferences in January 2022 (Press release, I-Mab Biopharma, DEC 31, 2021, View Source [SID1234597890]). Details of the conferences and management presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

40th Annual J.P. Morgan Healthcare Conference

Presentation: Tuesday, January 11, 2022, at 4:30 p.m. E.S.T.

Presenter: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director

Webcast link: View Source;kiosk=true The webcast will also be available under "Event Calendar" on IMAB’s IR website at View Source .

One-on-one and small group meetings: January 19-21, 2022

Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

For more information, please contact your J.P. Morgan representative.

Morgan Stanley Virtual China New Economy Summit 2022

One-on-one and small group meetings: January 5-7, 2022

Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

For more information, please contact your Morgan Stanley representative.

H.C. Wainwright Virtual BioConnect Conference

One-on-one and small group meetings: January 10 – 13, 2021

Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

For more information, please contact your H.C.Wainwright representative.

UBS Greater China Conference 2022

One-on-one and small group meetings: January 11-14, 2022

Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

For more information, please contact your UBS representative.

On December 31, 2021 GenFleet Therapeutics, a clinical-stage biotechnology company with a focus in cutting-edge therapies in oncology and immunology, reported the completion of $75 million (~500 million RMB) series C financing (Press release, GenFleet Therapeutics, DEC 31, 2021, View Source [SID1234597889]). This round of financing is led by Huagai Capital, with participation by new investors including Suxin Venture Capital, Cherami Investment Group, ABC International, DYEE Capital, Qiaojing Eastern Investment, Baidu Venture, and Wenzhou Capital. Existing investors including Lake Bleu Capital, Panlin Capital, Shanjin Asset, CDH Venture and Growth Capital, HM Capital also participated. Start Point Advisors act as the sole financial advisor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are grateful to Huagai Capital and other investors for their recognition of our strategy to develop cutting-edge therapies, our innovative discovery platform, and our differentiated pipeline in both small molecules and biologics. We believe that it is our unique strategy, platform and pipeline that can not only minimize but may even eliminate the uncertainties induced by the market fluctuations or investment cycles. We can therefore provide a sound foundation for continuous growth and to distinguish ourselves from an extremely competitive environment to bring to patients globally innovative therapies from China." said Dr. Qiang Lu, Co-founder and Chairman of GenFleet Therapeutics.

"GenFleet’s pipeline highlights our focuses in cutting-edge therapies with novel mechanisms and global IP. We have built a highly differentiated pipeline sustained by our proprietary discovery platform. As we expect more programs to move into late-stage clinical development in 2022, GenFleet will continue to march toward commercialization and globalization. We hope to help patients across the world through scientific breakthroughs and achieve positive financial results for our stakeholders." said Dr. Jiong Lan, Co-founder and Chief Executive Officer of GenFleet Therapeutics.

"HuaGai Capital feels honored to join GenFleet and to lead this round of financing. GenFleet is dedicated to serving unmet medical needs and we are impressed with its industry-leading progress as well as its efficient execution. Under the leadership of Dr. Lu and Dr. Lan, GenFleet truly stands out among competitors to bring life-saving treatments and better healthcare solutions to global patients." said Zhiqiang Zeng, Managing Partner of HuaGai Healthcare.

"We are pleased to lead this round of financing. GenFleet has established its proprietary R&D platform based on the deep understanding of disease biology and translational medicine. Its cutting-edge portfolio highlights innovative therapies with global IP, and we look forward to its prospects of globalization and long-term development in the industry." said Jingyang Zhu, Vice President of HuaGai Healthcare.

On December 30, 2021 Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as "Sumgen") reported that it has completed the series B + funding with over RMB 200 million (Press release, Sumgen Biotech, DEC 30, 2021, View Source;a=nav&id=247 [SID1234656269]). This funding is jointly invested by Junchuan Capital, Zheshang Venture Capital, Qianhai Wanhui and Wuxi Shangtong, and the existing investors Sinopharm CNBG, Hankang Capital and Addor Capital continue to add on. StartPointAdvisors has served as the exclusive financial adviser for this round of financing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sumgen is an innovation-driven biopharmaceutical company, which is committed to the development and commercialization of innovative antibody drugs for major diseases such as tumors. The company has continuous innovation capability and product export capability, and has established several innovation platforms, including several antibody discovery platforms such as mammalian cell display platform and BIMA (BI-specific/functional Macrophage Activator), BITA(BI-specific/functional T cell Activator).

Around the field of cancer, Sumgen has focused on the layout of a series of innovative products. SG301, SG404, SG12473 and other projects have completed the double report between China and the United States, entered the clinical study stage, and made positive progress; In November 2021, SG2501, the world’s first anti-CD38/CD47 bispecific antibody drug wholly developed by the company, was approved by FDA to carry out clinical study, and the clinical preparations for this project in the United States are progressing steadily. The company has carried out a global patent layout for innovative antibody drugs and declared more than 60 invention patents; and reached a number of commercial cooperations with CSPC and Sinopharm CNGB. At present, the company has started the construction of international standard production base, and is committed to providing high-quality Chinese antibodies for patients all over the world.

Dr. Lv Ming, founder and CEO of Sumgen, said: "Thanks to the new and old shareholders for their support to Sumgen. Sumgen will deepen the development of innovative products and accelerate the clinical layout in an all-round way; strengthen the sustainable source innovation ability and drive the development of enterprises with innovation; build industrial transformation ability and commercialization ability, and help enterprises build the whole industrial chain. "

On December 30, 2021 Polyphor and EnBiotix Inc. reported the closing of the merger of the two companies and the change of name of the combined company to Spexis AG (Press release, Polyphor, DEC 30, 2021, View Source [SID1234639732]). Pursuant to completion of the capital increase approved at the extraordinary general meeting of shareholders convened on October 28, 2021, Polyphor and EnBiotix, a privately held late clinical-stage rare disease company focused on products for rare, chronic respiratory diseases, have merged, via a transaction whereby Polyphor acquired 99.6% (with the remaining 0.4% expected to follow shortly) of the outstanding capital stock of EnBiotix in exchange for 35’150’961 shares of Polyphor common stock. The acquired capital stock of EnBiotix also includes shares issued by EnBiotix via the full conversion of the USD 11 million convertible debenture financing which was communicated on December 29, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Starting January 3, 2022, all 46’375’777 Spexis AG shares recorded in the commercial registry will be listed under the ticker symbol SPEX on the SIX Swiss Exchange under the International Reporting Standard and include all former Polyphor AG shares, which remain listed under the unchanged ISIN number (CH0106213793).

As resolved on October 28, 2021, by the Shareholders’ Meeting, Jeffrey Wager is replacing Kuno Sommer as chairman. Kuno Sommer and Bernard Bollag remain Board members. Dennis Ausiello has been elected vice-chair, Dan Hartman and Robert Clarke have also joined the Board thereby replacing Andreas Wallnöfer, Hugh O’Dowd, and Silvio Inderbitzin. The Executive Committee is led by Jeffrey Wager with Stephan Wehselau, Hernan Levett and Juergen Froehlich, thereby replacing Gökhan Batur, Franziska Müller, Daniel Obrecht and Frank Weber.

"We are pleased with the successful closing of the business combination and welcome the shareholders of EnBiotix and Polyphor to Spexis", said Jeffrey D. Wager, M.D., Chairman and Chief Executive Officer of Spexis. "We believe Spexis will pursue a unique strategy as a rare disease and oncology company. As such, we very much look forward to advancing an innovative R & D pipeline and to engaging in unique strategic corporate development to create long-term shareholder value."

The initial pipeline of Spexis includes:

– ColiFin(R) which EnBiotix has in-licensed from PARI Pharma GmbH, a global leader in nebulized therapies, for worldwide rights ex-Europe. Approved in Europe since 2010 as a front-line therapy for lung infections in cystic fibrosis ("CF"), ColiFin(R) has a proven safety, efficacy and commercial track record which the company aims to leverage towards the U.S. and global markets – and both within and outside the field of CF.

– Inhaled murepavadin, a novel class inhaled antibiotic specifically targeting Pseudomonas aeruginosa ("PA"), is being developed for the treatment of these infections in people with CF and is beginning Phase I development using eFlow(R) Technology nebulizer (PARI Pharma GmbH).

– EBX-002, a combination of amikacin (AMK) and a potentiator molecule for NTM infections which preclinical studies to date have shown potential for superior activity compared to ARYKACE(R).

– Balixafortide, a potent and highly selective blocker of CXCR4. Following the closure of its Phase 3 program in advanced breast cancer, additional oncology and non-oncology indications for balixafortide will be evaluated both alone and in collaboration with Fosun Pharma who owns China rights.

– New CXCR4 inhibitor program focused on orphan, hematological malignancies.

– Preclinical OMPTA BamA and LptA programs funded by CARBX targeting WHO Priority 1 bacterial infections planned to be developed for hospital acquired bacterial infections.

– Company aims to in-license or acquire other rare disease and oncology assets that will consolidate its position in these therapeutic areas.